XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash Flows From Operating Activities:    
Net loss $ (13,404) $ (3,527)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 5,365 4,837
Amortization of debt discount 643 264
Unrealized loss on investments in equity securities 4,908 263
Realized loss on available-for-sale investments 49 40
Stock-based compensation expense 4,125 2,990
Loss on disposal of property and equipment 92 71
Provision for bad debt 31 63
Insurance proceeds for operations 3,000  
Changes in operating assets and liabilities:    
Accounts receivable 3,340 (5,213)
Inventories (7,715) (988)
Prepaid expenses and other current assets 21 (6,545)
Deposits   229
Change in operating lease right-of-use assets and lease liabilities 5 60
Accounts payable and other accrued expenses (2,107) 532
Accrued compensation and related expenses 2,141 804
Deferred revenue (30) 49
Deferred tax liability 60 80
Net cash provided by (used in) operating activities 524 (5,991)
Cash Flows From Investing Activities:    
Purchases of property and equipment (4,245) (2,811)
Insurance proceeds for loss of fixed assets 2,000  
Software development costs (213) (193)
Purchases of short-term investments (30,354) (215,318)
Sales/maturities of short-term investments 36,000 3,000
Patent and trademark costs (138) (48)
Net cash provided by (used in) investing activities 3,050 (215,370)
Cash Flows From Financing Activities:    
Proceeds from exercise of stock options and warrants 313 1,586
Proceeds from public offering, net of $17.7 million in offering costs   269,825
Repurchase of common stock 8,349  
Repayment of finance lease liabilities (13) (18)
Net cash provided by (used in) financing activities (8,049) 271,393
Effect of exchange rates on cash and cash equivalents (178) (1,411)
Net change in cash and cash equivalents (4,653) 48,621
Cash and cash equivalents - beginning of period 139,101 36,873
Cash and cash equivalents - end of period 134,448 85,494
Supplemental Disclosure of Non-Cash Investing and Financing Activities:    
Conversion of Series C Preferred Stock to common stock   765
Cost of Series C Preferred stock conversion included in additional paid-in-capital and accounts payable and accrued liabilities   1,800
CRYOPDP goodwill adjustment included in deferred tax liability   1,394
MVE goodwill adjustment included in fixed assets   71
Note valuation adjustment included in note payable and goodwill   1,266
Net unrealized loss on available-for-sale securities 14,065 768
Reclassification of realized loss on available-for-sale debt securities to earnings 33 30
Paid-in-kind preferred stock dividend 2,000 2,196
Fixed assets included in accounts payable and accrued liabilities $ 549 $ 198